TABLE 1.

The evolution of ionizable lipids from permanently charged DOTMA to FDA‐approved DLin‐MC3‐DMA

Structure	Name	pKa	Ref
	DOTMA	—	40
	DODAP	5.8	45
	DLin‐DMA	6.8	46
	DLin‐KC2‐DMA	6.7	48
	DLin‐MC3‐DMA	6.4	49

Note: A complete overview on the more recent ionizable lipids synthesized and used in preclinical and clinical studies is presented in Reference [50].